Status:
UNKNOWN
Clinical Evaluation for Sarcoma Originated From Bone
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Xijing Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Sensitivity
Specificity
Eligibility:
All Genders
Brief Summary
Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating primary sarcoma originated from bone treated with chemotherapy or targeted therapy, which did not have the definitio...
Detailed Description
A total of 1570 lesions were evaluated by clinical imaging including X-ray, computed tomography, magnetic resonance imaging and bone scan or PET/CT preoperatively treated with chemotherapy. All patien...
Eligibility Criteria
Inclusion
- 1\) histologically confirmed high-grade osteosarcoma;
- 2\) initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital, Xijing Hospital or The Second Hospital affiliated to Zhejiang Hospital;
- 3\) imaging evaluation should be available;
- 4\) completed neo-adjuvant chemotherapy and at least 8 cycles of adjuvant chemotherapy;
- 5\) expected to live longer than 3 months with Eastern Cooperative Oncology Group performance status of 0 or 1;
- 6\) acceptable hematologic, hepatic, and renal function.
Exclusion
- 1\) Patients who could not complete neo-adjuvant chemotherapy or at least 4-month adjuvant chemotherapy;
- 2\) lost to follow-up.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2019
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03358992
Start Date
January 1 2018
End Date
March 30 2019
Last Update
November 14 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The second affliated Hospital of Zhejiang University School of medicine
Hangzhou, Zhejiang, China
2
Musculoskeletal Tumor Center of Peking University People's Hospital
Beijing, China, 100044
3
Xijing Hospital
Xi'an, China